In Segment C, individuals will get ABBV-744 and oral navitoclax. In Section D, individuals will get ABBV-744 and ruxolitinib. Individuals will receive treatment right until condition progression or even the individuals are not able to tolerate the study drugs. Celastrol was recognized as being a Myb inhibitor that suppressed C/EBPβ https://eminemf443sdn6.worldblogged.com/profile